Two Sigma Investments LP reduced its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 39.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 78,456 shares of the company’s stock after selling 50,630 shares during the period. Two Sigma Investments LP’s holdings in Amphastar Pharmaceuticals were worth $1,445,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at $139,000. Atria Investments LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at $190,000. Princeton Alpha Management LP purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at $195,000. Trexquant Investment LP purchased a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at $197,000. Finally, Smith Asset Management Group LP boosted its stake in shares of Amphastar Pharmaceuticals by 2.0% in the third quarter. Smith Asset Management Group LP now owns 11,990 shares of the company’s stock valued at $227,000 after buying an additional 230 shares in the last quarter. 49.09% of the stock is currently owned by institutional investors.
Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) opened at 14.27 on Tuesday. The firm has a 50 day moving average price of $15.49 and a 200 day moving average price of $18.12. Amphastar Pharmaceuticals Inc has a one year low of $11.25 and a one year high of $21.75. The stock has a market capitalization of $656.75 million, a PE ratio of 64.86 and a beta of 1.74.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Monday, March 13th. The company reported $0.01 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.02. Amphastar Pharmaceuticals had a return on equity of 6.79% and a net margin of 7.75%. The firm had revenue of $63.54 million for the quarter, compared to the consensus estimate of $55.78 million. During the same quarter last year, the business posted $0.19 earnings per share. The firm’s revenue was down 17.4% compared to the same quarter last year. Analysts predict that Amphastar Pharmaceuticals Inc will post $0.40 earnings per share for the current fiscal year.
AMPH has been the subject of several research reports. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 4th. BMO Capital Markets lowered their target price on Amphastar Pharmaceuticals from $18.00 to $16.00 and set a “market perform” rating for the company in a report on Tuesday, March 14th. Wells Fargo & Co reiterated an “outperform” rating and issued a $29.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a report on Wednesday, December 21st. Piper Jaffray Companies lowered their target price on Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 14th. Finally, Needham & Company LLC lowered their target price on Amphastar Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 14th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Amphastar Pharmaceuticals presently has an average rating of “Buy” and an average target price of $20.29.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).